Home › Calculator › BOVNF Dividend Calculator 2026
BOVNF Dividend DRIP Calculator 2026
60.82% YieldHealthcareBioInvent International AB (publ) · OTC
Price: $3.29 · Annual div: $2.00/share · Frequency: quarterly · Payout ratio: 50% · Ex-div: TBD
Calculator settings
Portfolio growth: DRIP vs No DRIP
Annual dividend income growth
💡 What-if scenarios
Click to apply scenario to the calculator
🎯 When BOVNF pays your bills
Year your monthly dividend income covers each expense (based on current settings)
Share your BOVNF snowball 📈
$10,000 in BOVNF → $63311.08M in 10 years · $5,124,600,921.60/month
About BioInvent International AB (publ) (BOVNF) — Dividend Analysis 2026
BioInvent International AB (publ) is a clinical-stage biotechnology company primarily focused on identifying, exploring, and engineering immunomodulatory antibodies to combat various forms of cancer. The company's activities extend globally, reaching markets in Sweden, across Europe, the United States, Japan, and other international regions. Its leading investigational compound is BI-1206, which is being developed to address both non-Hodgkin lymphoma and a range of solid tumors. Beyond this flagship program, BioInvent is advancing a diverse pipeline of therapeutic candidates. These include agents designed to target tumor-associated myeloid cells and cancer-associated regulatory T cells, which play a vital role in regulating the immune system. The company's portfolio also features BT-001 for solid tumor indications, as well as BI-1808 and BI-1910 – both anti-TNFR2 antibodies specifically intended for the treatment of solid tumors and cutaneous T-cell lymphoma. To further its development initiatives, BioInvent has established several key collaborations. It maintains a strategic alliance with Pfizer Inc. for the development of antibodies targeting tumor-associated myeloid cells. The company also collaborates with Transgene to jointly create innovative multi-functional oncolytic viruses aimed at solid tumors. Additionally, a collaboration and supply agreement with Merck facilitates the clinical advancement of BI-1808. Founded in 1996, BioInvent International AB (publ) maintains its headquarters in Lund, Sweden.
Compare BOVNF with similar stocks
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
Get Your Full BOVNF DRIP Report by Email
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open BOVNF position with:
🌍 BOVNF Yield by Country & Account Type
Real after-tax yield depends on where you live and how you hold BOVNF.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 60.82% | 58.02% | $6,082 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 51.70% | 48.90% | $5,170 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 48.66% | 45.86% | $4,866 / yr |
| 🇬🇧 UK ISA | 0% | 60.82% | 58.02% | $6,082 / yr |
| 🇬🇧 UK Taxable | 8.75% | 55.50% | 52.70% | $5,550 / yr |
| 🇨🇦 TFSA | 0% | 60.82% | 58.02% | $6,082 / yr |
| 🇨🇦 CA Taxable | 25% | 45.62% | 42.82% | $4,562 / yr |
| 🇦🇺 Super (pension) | 15% | 51.70% | 48.90% | $5,170 / yr |
| 🇦🇺 AU Taxable | 30% | 42.57% | 39.77% | $4,257 / yr |
| 🇩🇪 DE Taxable | 26.375% | 44.78% | 41.98% | $4,478 / yr |
| 🇫🇷 FR Taxable | 30% | 42.57% | 39.77% | $4,257 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
🎯 BOVNF Income Goal & Break-Even
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $2.00/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
📅 BOVNF Dividend Payment Schedule
BOVNF pays quarterly — 4 times per year. Next ex-div: TBD.
📊 BOVNF vs Healthcare Benchmarks
How BOVNF compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for BOVNF sourced from FMP /financial-growth endpoint — real data, not estimates.
🏛️ BOVNF Insider Activity
No recent SEC filings reported in the last 90 days.Financial Health Scores
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the BOVNF dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
BioInvent International AB (publ) (BOVNF) is currently trading at $3.29, 54% below its 52-week high. The current dividend yield is 60.82% based on an annual payout of $2.00 per share.
BOVNF (BioInvent International AB (publ)) — 60.82% Dividend Yield Analysis
BioInvent International AB (publ) (BOVNF) is a healthcare stock currently trading at $3.29 with a dividend yield of 60.82%. The company pays an annual dividend of $2.00 per share. The payout ratio of 50% suggests the dividend is well-covered by earnings.
- Above-average yield (60.82%) may signal elevated risk — verify sustainability.
Auto-generated from live market data. For educational purposes only — not financial advice.